Immunotherapy (e.g., PD-1 inhibitors)

Type: drug

Status: Investigational (for osteosarcoma)

Developer: Various pharmaceutical companies (e.g., Merck, Bristol Myers Squibb)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026